Lauroylethanolamide and linoleoylethanolamide improve functional outcome in a rodent model for stroke

Neuroscience Letters

Volumn 492, Issue 3, 2011, Pages 134-138

  Garg, Puja ^a   Duncan, R Scott ^a   Kaja, Simon ^a   Zabaneh, Alexander ^a   Chapman, Kent D ^b   Koulen, Peter ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Ischemia; Middle cerebral artery occlusion; N acylethanolamine; Neuroprotection

Indexed keywords

ETHANOLAMINE DERIVATIVE; LAUROYLETHANOLAMIDE; LINOLEOYLETHANOLAMIDE; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STROKE; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; ETHANOLAMINES; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; REPERFUSION INJURY; STROKE; TREATMENT OUTCOME;

EID: 79952438703     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.01.073     Document Type: Article

References (55)

1. ArunaDevi R., Lata S., Bhadoria B.K., Ramteke V.D., Kumar S., Sankar P., Kumar D., Tandan S.K. Neuroprotective effect of 5,7,3',4',5'-pentahydroxy dihydroflavanol-3-O-(2″-O-galloyl)-beta-d-glucopyranoside, a polyphenolic compound in focal cerebral ischemia in rat. Eur. J. Pharmacol. 2010, 626:205-212.
2. ArunaDevi R., Ramteke V.D., Kumar S., Shukla M.K., Jaganathan S., Kumar D., Sharma A.K., Tandan S.K. Neuroprotective effect of s-methylisothiourea in transient focal cerebral ischemia in rat. Nitric Oxide 2010, 22:1-10.
3. Berdyshev E.V., Schmid P.C., Dong Z., Schmid H.H. Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem. J. 2000, 346(Pt 2):369-374.
4. Berger C., Schmid P.C., Schabitz W.R., Wolf M., Schwab S., Schmid H.H. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?. J. Neurochem. 2004, 88:1159-1167.
5. Blancaflor E.B., Hou G., Chapman K.D. Elevated levels of N-lauroylethanolamine, an endogenous constituent of desiccated seeds, disrupt normal root development in Arabidopsis thaliana seedlings. Planta 2003, 217:206-217.
6. Calabresi P., Centonze D., Cupini L.M., Costa C., Pisani F., Bernardi G. Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies. Neurobiol. Dis. 2003, 12:82-88.
7. Calabresi P., Cupini L.M., Centonze D., Pisani F., Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann. Neurol. 2003, 53:693-702.
8. Candelario-Jalil E., Fiebich B.L. Cyclooxygenase inhibition in ischemic brain injury. Curr. Pharm. Des. 2008, 14:1401-1418.
9. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009, 158:983-994.
10. Chapman K.D., Moore T.S. N-acylphosphatidylethanolamine synthesis in plants: occurrence, molecular composition, and phospholipid origin. Arch. Biochem. Biophys. 1993, 301:21-33.
11. Degn M., Lambertsen K.L., Petersen G., Meldgaard M., Artmann A., Clausen B.H., Hansen S.H., Finsen B., Hansen H.S., Lund T.M. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J. Neurochem. 2007, 103:1907-1916.
12. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34:605-613.
13. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
14. Elewa H.F., Hilali H., Hess D.C., Machado L.S., Fagan S.C. Minocycline for short-term neuroprotection. Pharmacotherapy 2006, 26:515-521.
15. Garcia-Arencibia M., Garcia C., Fernandez-Ruiz J. Cannabinoids and Parkinson's disease. CNS Neurol. Disord. Drug Targets 2009, 8:432-439.
16. Garg P., Duncan R.S., Kaja S., Koulen P. Intracellular mechanisms of N-acylethanolamine-mediated neuroprotection in a rat model of stroke. Neuroscience 2010, 166:252-262.
17. Ginsberg M.D. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009, 40:S111-S114.
18. Gladstone D.J., Black S.E., Hakim A.M. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002, 33:2123-2136.
19. Guiffrida A., Piomelli D. Purification and High-Resolution Analysis of Anandamide and Other Fatty Acylethanolamides. Lipid Second Messengers 1999, CRC Press, Boca Raton.
20. Hansen H.H., Ikonomidou C., Bittigau P., Hansen S.H., Hansen H.S. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem. 2001, 76:39-46.
21. Hansen H.S., Lauritzen L., Strand A.M., Moesgaard B., Frandsen A. Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture. Biochim. Biophys. Acta 1995, 1258:303-308.
22. Heiss W.D. Ischemic penumbra: evidence from functional imaging in man. J. Cereb. Blood Flow Metab. 2000, 20:1276-1293.
23. Heiss W.D., Graf R., Grond M., Rudolf J. Quantitative neuroimaging for the evaluation of the effect of stroke treatment. Cerebrovasc. Dis. 1998, 8(Suppl. 2):23-29.
24. Hussain M.S., Shuaib A. Research into neuroprotection must continue. But with a different approach. Stroke 2008, 39:521-522.
25. Iuvone T., Esposito G., De Filippis D., Bisogno T., Petrosino S., Scuderi C., Di Marzo V., Steardo L. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. J. Mol. Med. 2007, 85:1379-1392.
26. Keereetaweep J., Kilaru A., Feussner I., Venables B.J., Chapman K.D. Lauroylethanolamide is a potent competitive inhibitor of lipoxygenase activity. FEBS Lett. 2010, 584:3215-3222.
27. Kirino T. Delayed neuronal death. Neuropathology 2000, 20(Suppl.):S95-S97.
28. P. Koulen, K.D. Chapman, Modulation of intracellular signaling by N-acylethanolamines, US Patent Publication No. US-2006-0142395-A1, 2006.
29. Lambert D.M., Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Curr. Med. Chem. 1999, 6:757-773.
30. Lambert D.M., Vandevoorde S., Jonsson K.O., Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Curr. Med. Chem. 2002, 9:663-674.
31. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., Ferguson T.B., Ford E., Furie K., Gillespie C., Go A., Greenlund K., Haase N., Hailpern S., Ho P.M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M.M., Meigs J., Mozaffarian D., Mussolino M., Nichol G., Roger V.L., Rosamond W., Sacco R., Sorlie P., Thom T., Wasserthiel-Smoller S., Wong N.D., Wylie-Rosett J. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
32. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 2000, 275:31938-31945.
33. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
34. McPartland J.M. Phylogenomic and chemotaxonomic analysis of the endocannabinoid system. Brain Res. Brain Res. Rev. 2004, 45:18-29.
35. Moesgaard B., Jaroszewski J.W., Hansen H.S. Accumulation of N-acyl-ethanolamine phospholipids in rat brains during post-decapitative ischemia: a 31p NMR study. J. Lipid Res. 1999, 40:515-521.
36. 2+ in endothelial cells. Br. J. Pharmacol. 1999, 126:1593-1600.
37. Movahed P., Jonsson B.A., Birnir B., Wingstrand J.A., Jorgensen T.D., Ermund A., Sterner O., Zygmunt P.M., Hogestatt E.D. Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J. Biol. Chem. 2005, 280:38496-38504.
38. Narita K., Kubota M., Nakane M., Kitahara S., Nakagomi T., Tamura A., Hisaki H., Shimasaki H., Ueta N. Therapeutic time window in the penumbra during permanent focal ischemia in rats: changes of free fatty acids and glycerophospholipids. Neurol. Res. 2000, 22:393-400.
39. Parinandi N.L., Schmid H.H. Effects of long-chain N-acylethanolamines on lipid peroxidation in cardiac mitochondria. FEBS Lett. 1988, 237:49-52.
40. Petullo D., Masonic K., Lincoln C., Wibberley L., Teliska M., Yao D.L. Model development and behavioral assessment of focal cerebral ischemia in rats. Life Sci. 1999, 64:1099-1108.
41. Savitz S.I. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol. 2007, 205:20-25.
42. Schmid H.H., Berdyshev E.V. Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:363-376.
43. Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maasson J.L., Schmid H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 1995, 375:117-120.
44. Schomacher M., Muller H.D., Sommer C., Schwab S., Schabitz W.R. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res. 2008, 1240:213-220.
45. Sheehan J.J., Tsirka S.E. Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. Glia 2005, 50:340-350.
46. Sinor A.D., Irvin S.M., Greenberg D.A. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 2000, 278:157-160.
47. Sughrue M.E., Grobelny B.T., Ducruet A.F., Komotar R.J., Mocco J., Sciacca R.R., Sander Connolly E. Data presentation in rodent stroke studies and the predictive value of confidence intervals. J. Clin. Neurosci. 2010, 17:11-15.
48. Sun Y., Alexander S.P., Garle M.J., Gibson C.L., Hewitt K., Murphy S.P., Kendall D.A., Bennett A.J. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br. J. Pharmacol. 2007, 152:734-743.
49. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., Sharp F.R. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 1990, 10:290-293.
50. Tsubokawa T., Jadhav V., Solaroglu I., Shiokawa Y., Konishi Y., Zhang J.H. Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Stroke 2007, 38:1057-1062.
51. Ueda N., Tsuboi K., Uyama T. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog. Lipid Res. 2010, 49:299-315.
52. Veldhuis W.B., van der Stelt M., Wadman M.W., van Zadelhoff G., Maccarrone M., Fezza F., Veldink G.A., Vliegenthart J.F., Bar P.R., Nicolay K., Di Marzo V. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 2003, 23:4127-4133.
53. Wen Y., Yang S., Liu R., Perez E., Yi K.D., Koulen P., Simpkins J.W. Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res. 2004, 1008:147-154.
54. Xu J., Culman J., Blume A., Brecht S., Gohlke P. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 2003, 34:1287-1292.
55. Zhang Y., Guo W.M., Chen S.M., Han L., Li Z.M. The role of N-lauroylethanolamine in the regulation of senescence of cut carnations (Dianthus caryophyllus). J. Plant Physiol. 2007, 164:993-1001.